Evommune Inc
EVMN
59 hedge funds and large institutions have $466M invested in Evommune Inc in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
86.29% more ownership
Funds ownership: 0% → 86.29% (+86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFM
EQT Fund Management
Luxembourg
|
+$92.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$65M |
| 3 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$36.2M |
| 4 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$27.1M |
| 5 |
JP Morgan Chase
New York
|
+$24.6M |
Top Sellers
EVMN Hedge Fund Activity: Q4 2025 in Review
59 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Evommune Inc (EVMN) for Q4 2025, worth a combined $466M.
Buyers outnumbered sellers: 59 funds opened new EVMN positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was EQT Fund Management, opening a new position worth an estimated $92.6M.
- 59 institutional investors held Evommune Inc (EVMN) as of Q4 2025, up from 0 in Q3 2025.
- Funds reported $466M of Evommune Inc stock for Q4 2025.
- 59 funds opened new Evommune Inc positions in Q4 2025 and 0 closed out, a net change of +59 holders.
- The largest Evommune Inc buyer in Q4 2025 was EQT Fund Management, an estimated $92.6M added.
Based on aggregated 13F filings for Q4 2025.